Andrew D J Pearson
Overview
Explore the profile of Andrew D J Pearson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
4696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bautista F, Verdu-Amoros J, Geoerger B, Rubio-San-Simon A, Paoletti X, Zwaan C, et al.
J Clin Oncol
. 2024 May;
42(21):2516-2526.
PMID: 38743911
Purpose: The aim of the Innovative Therapies for Children with Cancer (ITCC) consortium is to improve access to novel therapies for children and adolescents with cancer. The evolution of the...
2.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al.
J Clin Oncol
. 2024 Jan;
42(10):1135-1145.
PMID: 38190578
Purpose: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic...
3.
Pearson A, de Rojas T, Karres D, Reaman G, Scobie N, Fox E, et al.
J Natl Cancer Inst
. 2023 Nov;
116(2):200-207.
PMID: 37975877
In a landscape of an increasing number of products and histology and age agnostic trials for rare patient cancer, prioritization of products is required. Paediatric Strategy Forums, organized by ACCELERATE...
4.
de Rojas T, Chiodin D, Pearson A, Heenen D, Adamson P, Caron H, et al.
Clin Pharmacol Ther
. 2023 Oct;
115(1):36-41.
PMID: 37885401
Better therapies for childhood cancer remain an unmet need to improve the dismal prognosis of certain malignancies and to reduce the burden of toxicity. Rescuing discontinued or shelved drugs for...
5.
Pearson A, Federico S, Gatz S, Ortiz M, Lesa G, Scobie N, et al.
Eur J Cancer
. 2023 Jul;
190:112950.
PMID: 37441939
DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance...
6.
Moreno L, Dubois S, Glade Bender J, Mauguen A, Bird N, Buenger V, et al.
J Clin Oncol
. 2023 Apr;
41(18):3408-3422.
PMID: 37015036
Purpose: There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious...
7.
Vassal G, de Rojas T, Pearson A
Lancet Child Adolesc Health
. 2023 Jan;
7(3):214-222.
PMID: 36682367
The European Paediatric Medicine Regulation was launched in 2007, aiming to provide better medicines for children. However, its benefit for paediatric patients with cancer has been questioned and the European...
8.
Nader J, Bourgeois F, Bagatell R, Moreno L, Pearson A, Dubois S
Pediatr Blood Cancer
. 2022 Dec;
70(5):e30106.
PMID: 36458672
Background: Understanding the landscape of clinical trials for patients with neuroblastoma may inform efforts to improve drug development. Procedure: We evaluated therapeutic trials for patients with neuroblastoma from 2011 to...
9.
10.
Pearson A, de Rojas T, Karres D, Reaman G, Scobie N, Fox E, et al.
Lancet Oncol
. 2022 Nov;
23(11):1354-1357.
PMID: 36328007
No abstract available.